NCT05168930View on ClinicalTrials.gov

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

October 28, 2025

Study Completion Date

October 28, 2028

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
DRUG

Venetoclax

C4-15

DRUG

Zanubrutinib

C1-15

Trial Locations (4)

04074

RECRUITING

New England Cancer Specialists, Scarborough

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

02190

RECRUITING

South Shore Hospital, South Weymouth

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER